Caroline Palm-Apergi
Overview
Explore the profile of Caroline Palm-Apergi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
283
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Shah K, Nasimian A, Ahmed M, Al Ashiri L, Denison L, Sime W, et al.
Blood Cancer J
. 2023 Sep;
13(1):139.
PMID: 37679323
The deregulation of BCL2 family proteins plays a crucial role in leukemia development. Therefore, pharmacological inhibition of this family of proteins is becoming a prevalent treatment method. However, due to...
3.
Palm-Apergi C, Dowdy S
Methods Mol Biol
. 2021 Nov;
2383:257-264.
PMID: 34766295
The ability to deliver or transduce proteins into cells allows for the manipulation of cell biology in culture, preclinical models, and potentially human disease. Fusion proteins containing the TAT peptide...
4.
Goroshchuk O, Kolosenko I, Kunold E, Vidarsdottir L, Pirmoradian M, Azimi A, et al.
FASEB J
. 2021 Jun;
35(7):e21741.
PMID: 34143546
Polo-like kinase 1 (PLK1) is an important cell cycle kinase and an attractive target for anticancer treatments. An ATP-competitive small molecular PLK1 inhibitor, volasertib, has reached phase III in clinical...
5.
Kolosenko I, Goroshchuk O, Vidarsdottir L, Bjorklund A, Dowdy S, Palm-Apergi C
FASEB J
. 2021 Mar;
35(5):e21476.
PMID: 33788972
Polo-like kinase 1 (Plk1) is an important regulator of the cell cycle and it is frequently overexpressed in cancer cells. Several small molecule inhibitors have been developed to target Plk1...
6.
Kolosenko I, Palm-Apergi C
Future Med Chem
. 2020 Jul;
12(16):1457-1460.
PMID: 32638616
No abstract available.
7.
Goroshchuk O, Vidarsdottir L, Bjorklund A, Hamil A, Kolosenko I, Dowdy S, et al.
Sci Rep
. 2020 Feb;
10(1):2688.
PMID: 32060361
B-cell acute lymphoblastic leukemia (B-ALL) accounts for nearly one fifth of all childhood cancers and current challenges in B-ALL treatment include resistance, relapse and late-onset side effects due to the...
8.
Vidarsdottir L, Goroshchuk O, Kolosenko I, Palm-Apergi C
Methods Mol Biol
. 2019 Aug;
2036:53-72.
PMID: 31410790
The discovery of the RNA interference (RNAi) pathway followed by the usage of synthetic short-interfering RNAs (siRNA) has contributed greatly to the understanding of gene function. Carefully designed siRNAs can...
9.
Edsbacker E, Serviss J, Kolosenko I, Palm-Apergi C, De Milito A, Pokrovskaja Tamm K
Sci Rep
. 2019 Jan;
9(1):536.
PMID: 30679726
Three-dimensional cell cultures, such as multicellular spheroids (MCS), reflect the in vivo architecture of solid tumours and multicellular drug resistance. We previously identified interferon regulatory factor 9 (IRF9) to be...
10.
Goroshchuk O, Kolosenko I, Vidarsdottir L, Azimi A, Palm-Apergi C
Oncogene
. 2018 Aug;
38(1):1-16.
PMID: 30104712
Acute leukemia is a common malignancy among children and adults worldwide and many patients suffer from chronic health issues using current therapeutic approaches. Therefore, there is a great need for...